Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced that it has commenced an underwritten public offering of 2,000,000 shares of its common stock. All of the shares in the offering are to be sold by Agios. Agios intends to grant the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock sold in the offering. The proceeds of the offering are expected to be used to fund the company's clinical and research development activities. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. - updated 4/24 - Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced the pricing of its underwritten public offering of 2,000,000 shares of its common stock at a public offering price of $44.00 per share, before underwriting discounts. All of the shares in the offering are to be sold by Agios. In addition, Agios has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock at the public offering price, less the underwriting discount.
Agios Pharmaceuticals is a biopharmaceutical company committed in the field of cellular metabolism to transform the lives of patients with cancer and inborn errors of metabolism, or IEMs, which are a subset of orphan genetic metabolic diseases. Metabolism is a complex biological process involving the uptake and assimilation of nutrients in cells to produce energy and facilitate many of the processes required for cellular division and growth. Co. singularly focuses its efforts on using cellular metabolism, an unexploited area of biological research as a platform for developing potentially transformative small molecule medicines for cancer and IEMs.
Open the AGIO Page at The Online Investor »
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20
minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.